Novavax stock: Sanofi milestone lifts 2026 revenue outlook

Published on 11/06/2026 at 22:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novavax stock drew attention after a Sanofi milestone was triggered by a combination-vaccine trial. The company raised its 2026 revenue outlook.

Novavax raises revenue outlook

Sanofi's combination-vaccine trial generated a major milestone for Novavax.
Third-quarter losses narrowed as research and selling costs declined.
Further milestone payments depend on technology transfer and a potential US launch.

NVAX, US6700024010, Illustration mit AI erstellt.

Novavax raised its 2026 adjusted revenue framework after Sanofi began a Phase 3 European trial combining Nuvaxovid with a high-dose flu vaccine. Zacks Equity Research reported the development on Friday, November 6, citing a milestone payment tied to the partner program.

Sanofi deal reshapes the outlook

The revised framework calls for adjusted 2026 revenue of USD 385 million to USD 415 million, compared with the previous range of USD 235 million to USD 275 million. The milestone associated with the Sanofi trial accounts for most of the increase, while higher product sales and licensing revenue provide the remainder.

Sanofi is targeting a US Phase 3 study in 2027, according to management remarks reported by MarketBeat. A successful path to a first US commercial sale could generate another milestone, while completion of the manufacturing technology transfer is tied to a separate payment targeted for mid-2027.

Loss narrows as costs fall

Novavax reported third-quarter revenue of USD 68 million, down from USD 70 million a year earlier, while the net loss narrowed to USD 31 million from USD 202 million. The prior-year result included substantial noncash charges related to asset impairments and debt extinguishment.

Research and development and selling, general and administrative expenses both declined as Sanofi assumed more commercial responsibilities and related support work approached completion. Management also outlined a longer-term plan to reduce the combined non-GAAP expense base and expects its cash runway to extend into 2029.

Novavax stock traded at 9.65 euros on Lang & Schwarz at 10:22 p.m. CET on Friday, November 6. Investors are likely to focus next on Sanofi's clinical progress, the planned technology transfer and the company's ability to convert partnership milestones into recurring revenue. The real-time quote of Novavax stock provides the latest trading indication.